Eledon Pharma reports FY2021 net loss of $34.5M; cash $84.8M into 2024

Eledon Pharmaceuticals, Inc.

Net loss for Q4 2021 was $8.8M ($0.59/share); FY2021 net loss $34.5M ($2.33/share).
R&D expense rose to $23.7M in FY2021 from $6.1M in FY2020, driven by tegoprubart trials.
Cash and equivalents $84.8M at Dec 31, 2021, down from $114.2M a year earlier.
Topline Phase 2a tegoprubart data in ALS expected in Q2 2022; kidney, IgAN, islet data in Q4 2022.
No revenue recorded; net loss widened due to increased clinical development costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.